Sudarshan Pharma Industries Ltd (SPIL) has been granted 'One Star Export House' status by the Ministry of Commerce and ...

Ankit Aggarwal is an Executive Director at J.P. Morgan in New York, where he leads capital markets and strategic advisory for ...

The UCPMP was introduced in March last year with an objective to bring about transparency and ensure ethical conduct in the ...

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring ...

Targeting a corpus of INR 200 crore, with a greenshoe option of INR 100 crore, the fund aims to support early-stage biotech companies in India. The portfolio will comprise 20-25 B2B startups ...

We are in an age where medicine is no longer one-size-fits-all; personalised healthcare is changing the diagnosis and ...

to scout for new destinations such as India. Anthem says it works with several small and emerging biotech companies and a handful of big names such as Bayer. Like Aragen, it plans to ramp up the ...

and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two ...

The United States has a $115.5 billion trade deficit in pharmaceutical products, which the Trump administration has suggested it may try to equalize through tariffs.

The company is expanding its focus ... in large batches for the wider population. Bharat Biotech said it intends to focus more on the latter. India, compared to global peers, is still in the ...

Regardless of the bill’s fate, there appears to be a mandate for US biotech companies to shift their businesses away from China to other locations. India could be one of the destinations if it ...